| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $87.7M | +50.0% |
| SG&A Expense | $25.4M | +193.1% |
| Operating Income | -$113.1M | -68.5% |
| Net Income | -$108.4M | -29.5% |
| EPS (Basic) | -$2.07 | +68.9% |
| EPS (Diluted) | -$2.07 | +68.9% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $64.8M | -8.4% |
| Short-term Investments | $253.1M | +34.8% |
| Current Assets | $330.7M | +25.7% |
| Total Assets | $371.4M | +27.4% |
| Current Liabilities | $16.4M | +33.2% |
| Total Liabilities | $17.5M | +42.5% |
| Stockholders' Equity | $353.9M | +26.8% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$98.8M | -155.6% |
| Capital Expenditures | $275K | +5.0% |
| Investing Cash Flow | -$74.9M | +65.0% |
| Financing Cash Flow | $167.8M | -48.1% |
| Free Cash Flow | -$99.0M | -154.5% |